

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	4592461
<b>Application Number:</b>	10530232
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	1265
<b>Title of Invention:</b>	5-HT 1b/1d receptor agonists for the treatment of headache resulting from administering an endothelin receptor antagonist
<b>First Named Inventor/Applicant Name:</b>	Jon Owen Curwen
<b>Customer Number:</b>	44992
<b>Filer:</b>	Jacob G. Weintraub
<b>Filer Authorized By:</b>	
<b>Attorney Docket Number:</b>	100853-1P US
<b>Receipt Date:</b>	12-JAN-2009
<b>Filing Date:</b>	04-APR-2005
<b>Time Stamp:</b>	14:14:26
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement (IDS) Filed (5B/08)	100853IDS.pdf	937562 4016a89d95090366378729a2abf3aa3553 460a	no	4

**Warnings:**

**Information:**

A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.

2	NPL Documents	BrJClinPharmacol20023553625 3.pdf	405714 5802f5ea1b5d713a0baa9445e15ced093d ae1ef	no	8
<b>Warnings:</b>					
<b>Information:</b>					
3	NPL Documents	AmJMed2002135140112.pdf	396785 6b2630688c7b18b1848986c2b8d8dc71ac7 d38	no	6
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	JMedChem199799100440.pdf	619281 e9b0a0e0ca301615d55c7dbd63711108f5 9d36	no	9
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	InvestNewDrugs200217318220 .pdf	559968 73687db76196db63db7b18381c25a29c e6b2	no	10
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	ClinicalScience20023065309S1 03Suppl48.pdf	210928 57a9fc55d8e75cc730c8f65655b6d5ea82 a6095	no	4
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			3130238		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.